These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2580154)

  • 1. Actions of two new bradycardic agents, AQ-AH 208 and UL-FS 49, on ischemic myocardial perfusion and function.
    Dämmgen JW; Lamping KA; Gross GJ
    J Cardiovasc Pharmacol; 1985; 7(1):71-9. PubMed ID: 2580154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of AQ-AH 208, a new specific bradycardic agent, on myocardial ischemia-reperfusion injury in anesthetized dogs.
    Gross GJ; Warltier DC; Daemmgen JW
    J Cardiovasc Pharmacol; 1985; 7(5):929-36. PubMed ID: 2413303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of two specific bradycardic agents AQ-A39 (falipamil) and AQ-AH 208 on reversible myocardial reperfusion damage in anesthetized dogs.
    Gross GJ; Daemmgen JW
    J Pharmacol Exp Ther; 1986 Aug; 238(2):422-8. PubMed ID: 3735124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional redistribution of myocardial perfusion by UL-FS 49, a selective bradycardic agent.
    O'Brien P; Drage D; Saeian K; Brooks HL; Warltier DC
    Am Heart J; 1992 Mar; 123(3):566-74. PubMed ID: 1539507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent".
    Kobinger W; Lillie C
    Eur J Pharmacol; 1984 Sep; 104(1-2):9-18. PubMed ID: 6499920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AQ-AH 208, a new bradycardic agent, increases coronary collateral blood flow to ischemic myocardium.
    Daemmgen JW; Gross GJ
    J Cardiovasc Pharmacol; 1985; 7(6):1048-54. PubMed ID: 2418287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of a potassium channel blocking drug, UK-68,798, and a specific bradycardic agent, UL-FS 49, on exercise-induced ischemia in the dog: significance of diastolic time on ischemic cardiac function.
    Gout B; Jean J; Bril A
    J Pharmacol Exp Ther; 1992 Sep; 262(3):987-94. PubMed ID: 1527735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of bradycardic agents on ischaemic myocardium and perfusion in anesthetized dogs.
    Gross GJ; Daemmgen JW
    Eur Heart J; 1987 Dec; 8 Suppl L():69-74. PubMed ID: 3451885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bradycardic agent UL-FS 49 attenuates ischemic regional myocardial dysfunction and reduces infarct size in swine: comparison with the beta-blocker atenolol.
    Schulz R; Rose J; Skyschally A; Heusch G
    J Cardiovasc Pharmacol; 1995 Feb; 25(2):216-28. PubMed ID: 7752647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the new specific bradycardia agent AQ-A39 (falipamil) on coronary collateral blood flow in dogs.
    Gross GJ; Daemmgen JW
    J Cardiovasc Pharmacol; 1987 Jul; 10(1):123-7. PubMed ID: 2441148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bradycardic agent, UL-FS 49, increases atrial force and decreases ventricular force in isolated, perfused heart preparations of dogs.
    Furukawa Y; Takayama S; Sawaki S; Inoue Y; Chiba S
    J Pharmacol Exp Ther; 1993 May; 265(2):801-6. PubMed ID: 8496825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigations into the bradycardic effects of UL-FS 49 (1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-[[2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on-hydrochloride) in isolated guinea pig atria.
    Lillie C; Kobinger W
    J Cardiovasc Pharmacol; 1986; 8(4):791-7. PubMed ID: 2427820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular actions of 5,6-dimethoxy-2-(3-[(alpha-(3,4-dimethoxy) phenylethyl)-methylamino] propyl) phthalimidine (AQ-A 39), a specific bradycardic agent.
    Dämmgen J; Kadatz R; Diederen W
    Arzneimittelforschung; 1981; 31(4):666-70. PubMed ID: 7195712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zatebradine, a specific bradycardic agent, enhances the positive inotropic actions of dobutamine in ischemic myocardium.
    Wynsen JC; O'Brien PD; Warltier DC
    J Am Coll Cardiol; 1994 Jan; 23(1):233-41. PubMed ID: 8277087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the 'specific bradycardic agent' alinidine on the function of ischemic myocardium.
    Schad H; Heimisch W; Haas F; Mendler N
    Thorac Cardiovasc Surg; 1991 Dec; 39 Suppl 3():211-6. PubMed ID: 1803632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elimination of exercise-induced regional myocardial dysfunction by a bradycardiac agent in dogs with chronic coronary stenosis.
    Guth BD; Heusch G; Seitelberger R; Ross J
    Circulation; 1987 Mar; 75(3):661-9. PubMed ID: 3815774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of improved ischemic regional dysfunction by bradycardia. Studies on UL-FS 49 in swine.
    Indolfi C; Guth BD; Miura T; Miyazaki S; Schulz R; Ross J
    Circulation; 1989 Oct; 80(4):983-93. PubMed ID: 2791256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of heart rate reduction in the treatment of exercise-induced myocardial ischaemia.
    Guth BD; Heusch G; Seitelberger R; Matsuzaki M; Ross J
    Eur Heart J; 1987 Dec; 8 Suppl L():61-8. PubMed ID: 3451884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of benefit in the ischemic myocardium due to heart rate reduction.
    Guth BD; Indolfi C; Heusch G; Seitelberger R; Ross J
    Basic Res Cardiol; 1990; 85 Suppl 1():157-66. PubMed ID: 1965395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the bradycardic agent UL-FS 49 on exercise-induced regional contractile dysfunction in dogs.
    Raberger G; Krumpl G; Schneider W
    Int J Cardiol; 1987 Mar; 14(3):343-54. PubMed ID: 3557712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.